The FDA has granted approval to Amring Pharmaceuticals Inc. for its generic lamotrigine ODT, according to a press release. The treatment is indicated for epilepsy adjunctive therapy in patients aged 2 years and older, epilepsy monotherapy in patients aged 16 years and older and maintenance of bipolar I disorder in patients treated for acute mood episodes with standard therapy.
Amzell, B V , in Collaboration With Amring Pharmaceuticals Inc Announce Their Lead Product Has Entered Phase III Clinical Trial in the U S for Treatment of Infantile Epileptic Disease
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Amring Pharmaceuticals Inc Announces the Approval and Launch of Generic Isoproterenol Hydrochloride
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Amring Pharmaceuticals Inc. Enters into License and Development Agreement with Amzell B.V.
March 12, 2021 GMT
BERWYN, Pa. (BUSINESS WIRE) Mar 12, 2021
Amring Pharmaceuticals Inc. (Amring), a niche brand and generic pharmaceutical company, announced today an agreement with Amzell B.V. (Amzell) that will further strengthen its position in the marketplace with the commercial rights to one of Amzell’s leading clinical-stage programs that will bring a critical and accessible therapy for patients in need. Under this agreement Amzell will complete the full clinical development of the product in specific markets and Amring will commercialize the product. Amring will invest an undisclosed amount in the development through the clinical phase and FDA approval process.